Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer.
10.3349/ymj.2011.52.4.695
- Author:
Yun Hong CHEON
1
;
Moon Jin KIM
;
Min Gyu KANG
;
Hee Jin KIM
;
Sang Su LEE
;
Cha Young KIM
;
Dae Hong JEON
;
Yu Eun KIM
;
Gyeong Won LEE
Author Information
1. Department of Internal Medicine, School of Medicine, Gyeongsang National University, Jinju, Korea. brightree@lycos.co.kr
- Publication Type:Case Report
- Keywords:
Lung neoplasm;
intestinal fistula;
erlotinib
- MeSH:
Aged;
Antineoplastic Agents/*adverse effects/therapeutic use;
Carcinoma, Non-Small-Cell Lung/complications/*drug therapy;
Female;
Humans;
Intestinal Fistula/*chemically induced/complications/radiography/surgery;
Intestinal Perforation/*chemically induced/complications/radiography/surgery;
Protein Kinase Inhibitors/*adverse effects/therapeutic use;
Quinazolines/*adverse effects/therapeutic use;
Sigmoid Diseases/*chemically induced/complications/radiography/surgery
- From:Yonsei Medical Journal
2011;52(4):695-698
- CountryRepublic of Korea
- Language:English
-
Abstract:
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.
